TDP-43 modification in the hSOD1G93A amyotrophic lateral sclerosis mouse model

Neurological Research

Volumn 37, Issue 3, 2015, Pages 253-262

  Cai, Mu Dan ^a   Lee, Kang Woo ^a   Choi, Sun Mi ^a   Yang, Eun Jin ^a  

^a Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

hSOD1G93A; Iron homeostasis; Motor neuron; TDP 43

Indexed keywords

TAR DNA BINDING PROTEIN; TRANSFERRIN; COPPER ZINC SUPEROXIDE DISMUTASE; DNA BINDING PROTEIN; HEME OXYGENASE 1; HMOX1 PROTEIN, MOUSE; IRON; MEMBRANE PROTEIN; SUPEROXIDE DISMUTASE; TDP-43 PROTEIN, MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; ANIMAL; BLOOD; BRAIN STEM; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; PHOSPHORYLATION; SPINAL CORD; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ASTROCYTES; BRAIN STEM; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; HEME OXYGENASE-1; HUMANS; IRON; MALE; MEMBRANE PROTEINS; MICE, TRANSGENIC; MICROGLIA; OXIDATIVE STRESS; PHOSPHORYLATION; SPINAL CORD; SUPEROXIDE DISMUTASE; TRANSFERRIN;

EID: 84920106094     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132814Y.0000000443     Document Type: Article

References (42)

1. Redler RL, Dokholyan NV. The complex molecular biology of amyotrophic lateral sclerosis (ALS). Prog Mol Biol Transl Sci. 2012;107:215–62.
2. Eisen A. Amyotrophic lateral sclerosis. Intern Med. 1995;34:824–32.
3. Ryu H, Ferrante RJ. Translational therapeutic strategies in amyotrophic lateral sclerosis. Mini Rev Med Chem. 2007;7:141–50.
4. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al.Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59–62.
5. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772–5.
6. Da Cruz S, Cleveland DW. Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. Curr Opin Neurobiol. 2011;21:904–19.
7. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40:572–4.
8. Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, Xu Y, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117:137–49.
9. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130–3.
10. Brady OA, Meng P, Zheng Y, Mao Y, Hu F. Regulation of TDP-43 aggregation by phosphorylation and p62/SQSTM1. J Neurochem. 2011;116:248–59.
11. Kraemer BC, Schuck T, Wheeler JM, Robinson LC, Trojanowski JQ, Lee VM, et al. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol. 2010;119:409–19.
12. Igaz LM, Kwong LK, Xu Y, Truax AC, Uryu K, Neumann M, et al. Enrichment of C-terminal fragments in TAR DNAbinding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol. 2008;173:182–94.
13. Li X, Jankovic J, Le W. Iron chelation and neuroprotection in neurodegenerative diseases. J Neural Transm. 2011;118:473–7.
14. Oshiro S, Morioka MS, Kikuchi M. Dysregulation of iron metabolism in Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Adv Pharmacol Sci. 2011;2011:378278.
15. Crichton RR, Charloteaux-Wauters M. Iron transport and storage. Eur J Biochem. 1987;164:485–506.
16. Yang EJ, Jiang JH, Lee SM, Yang SC, Hwang HS, Lee MS, et al. Bee venom attenuates neuroinflammatory events and extends survival in amyotrophic lateral sclerosis models. J Neuroinflammation. 2010;7:69.
17. Schmued LC, Albertson C, Slikker W Jr. Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res. 1997;751:37–46.
18. Hopkins KJ, Wang G, Schmued LC. Temporal progression of kainic acid induced neuronal and myelin degeneration in the rat forebrain. Brain Res. 2000;864:69–80.
19. Yang EJ, Kim SH, Yang SC, Lee SM, Choi SM. Melittin restores proteasome function in an animal model of ALS. J Neuroinflammation. 2011;8:69.
20. Zhang X, Chen S, Li L, Wang Q, Le W. Decreased level of 5- methyltetrahydrofolate: a potential biomarker for pre-symptomatic amyotrophic lateral sclerosis. J Neurol Sci. 2010;293:102–5.
21. Feng XH, Yuan W, Peng Y, Liu MS, Cui LY. Therapeutic effects of DL-3-N-butylphthalide in a transgenic mouse model of amyotrophic lateral sclerosis. Chin Med J. 2012;125:1760–6.
22. Kasarskis EJ, Tandon L, Lovell MA, Ehmann WD. Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: a preliminary study. J Neurol Sci. 1995;130:203–8.
23. Shaw CE, al-Chalabi A, Leigh N. Progress in the pathogenesis of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep. 2001;1:69–76.
24. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive taunegative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602–11.
25. Zhang YJ, Xu YF, Cook C, Gendron TF, Roettges P, Link CD, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A. 2009;106:7607–12.
26. Valdmanis PN, Daoud H, Dion PA, Rouleau GA. Recent advances in the genetics of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep. 2009;9:198–205.
27. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008;11:251–3.
28. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10:615–22.
29. Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci. 2007;10:608–14.
30. Van Damme P, Bogaert E, Dewil M, Hersmus N, Kiraly D, Scheveneels W, et al. Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proc Natl Acad Sci U S A. 2007;104:14825–30.
31. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol. 1995;38:73–84.
32. Swarup V, Phaneuf D, Bareil C, Robertson J, Rouleau GA, Kriz J, et al. Pathological hallmarks of amyotrophic lateral sclerosis/ frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain. 2011;134:2610–26.
33. Esmaeili MA, Panahi M, Yadav S, Hennings L, Kiaei M. Premature death of TDP-43 (A315T) transgenic mice due to gastrointestinal complications prior to development of full neurological symptoms of amyotrophic lateral sclerosis. Int J Exp Pathol. 2013;94:56–64.
34. Xu YF, Zhang YJ, Lin WL, Cao X, Stetler C, Dickson DW, et al. Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice. Mol Neurodegener. 2011;6:73.
35. Tong J, Huang C, Bi F, Wu Q, Huang B, Liu X, et al. Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in rats. EMBO J. 2013;32:1917–26.
36. Yamashita T, Hideyama T, Hachiga K, Teramoto S, Takano J, Iwata N, et al. A role for calpain-dependent cleavage of TDP- 43 in amyotrophic lateral sclerosis pathology. Nat Commun. 2012;3:1307.
37. Tradewell ML, Durham HD. Calpastatin reduces toxicity of SOD1G93A in a culture model of amyotrophic lateral sclerosis. Neuroreport. 2010;21:976–9.
38. Weinreb O, Amit T, Mandel S, Youdim MB. Novel therapeutic approach for neurodegenerative pathologies: multitarget ironchelating drugs regulating hypoxia-inducible factor 1 signal transduction pathway. Neurodegener Dis. 2012;10:112–5.
39. Arduino D, Silva D, Cardoso SM, Chaves S, Oliveira CR, Santos MA. New hydroxypyridinone iron-chelators as potential anti-neurodegenerative drugs. Front Biosci. 2008;13:6763–74.
40. Wang Q, Zhang X, Chen S, Zhang X, Zhang S, Youdium M, et al. Prevention of motor neuron degeneration by novel iron chelators in SOD1(G93A) transgenic mice of amyotrophic lateral sclerosis. Neurodegener Dis. 2011;8:310–21.
41. Danzeisen R, Achsel T, Bederke U, Cozzolino M, Crosio C, Ferri A, et al. Superoxide dismutase 1 modulates expression of transferrin receptor. J Biol Inorg Chem. 2006;11:489–98.
42. Núñez MT, Urrutia P, Mena N, Aguirre P, Tapia V, Salazar J. Iron toxicity in neurodegeneration. Biometals. 2012;25:761–76.